Repligen Corporation $RGEN Stock: William Blair Investment Management LLC Raises Stake

William Blair Investment Management LLC boosted its stake in Repligen Corporation (NASDAQ:RGEN – Free Report) by 57.7% in the 3rd quarter, Holdings Channel reports. The firm owned 1,243,415 shares of the biotechnology company’s stock after acquiring an additional 454,844 shares during the quarter. Repligen accounts for approximately 0.8% of William Blair Investment Management LLC’s portfolio, making the stock its 23rd largest position. William Blair Investment Management LLC’s holdings in Repligen were worth $239,022,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. United Capital Financial Advisors LLC purchased a new stake in shares of Repligen in the second quarter worth about $380,756,000. Maverick Capital Ltd. bought a new position in shares of Repligen in the first quarter valued at approximately $178,946,000. Bamco Inc. NY bought a new position in shares of Repligen in the second quarter valued at approximately $102,121,000. TimesSquare Capital Management LLC bought a new position in shares of Repligen in the second quarter valued at approximately $60,984,000. Finally, Bank of America Corp DE purchased a new position in Repligen during the second quarter valued at approximately $58,163,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on RGEN. UBS Group reaffirmed a “buy” rating on shares of Repligen in a report on Tuesday, September 29th. Wells Fargo & Company increased their target price on shares of Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Canaccord Genuity Group raised their price target on shares of Repligen from $145.00 to $180.00 and gave the company a “hold” rating in a report on Monday, October 19th. Royal Bank Of Canada boosted their price target on shares of Repligen from $185.00 to $200.00 and gave the company an “outperform” rating in a research report on Wednesday, October 28th. Finally, Weiss Ratings cut shares of Repligen from a “hold (c)” rating to a “sell (d+)” rating in a report on Monday, November 2nd. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $178.57.

Check Out Our Latest Research Report on Repligen

Repligen Price Performance

RGEN stock opened at $167.79 on Monday. The firm has a 50 day simple moving average of $177.15 and a two-hundred day simple moving average of $145.67. Repligen Corporation has a one year low of $100.99 and a one year high of $198.87. The company has a debt-to-equity ratio of 0.27, a current ratio of 9.88 and a quick ratio of 8.43. The stock has a market cap of $10.73 billion, a PE ratio of -798.96, a P/E/G ratio of 2.88 and a beta of 1.11.

Repligen (NASDAQ:RGEN – Get Free Report) last announced its quarterly earnings data on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.07. Repligen had a negative net margin of 1.47% and a positive return on equity of 5.49%. The company had revenue of $209.31 million during the quarter, compared to analysts’ expectations of $206.70 million. During the same quarter in the prior year, the company earned $0.46 EPS. The firm’s revenue was up 10.9% on a year-over-year basis. On average, analysts predict that Repligen Corporation will post 2.07 EPS for the current fiscal year.

Repligen Company Profile

(Free Report)

Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.

Further Reading

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN – Free Report).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.